Successful investors buy low and sell high. It sounds simple, but neither task is easy to do in real time.
I am constantly singing the praises of put selling as a strategy for generating consistent income, but it can also be used to buy stocks when prices fall to bargain levels.
Buying low can be especially difficult when the market is selling off. Many investors decide to wait for even lower prices. The result is that many end up holding cash much longer than they expected.
But I know an easier way to buy low in a market that's pulling back. By selling puts when prices are high, investors are forced to buy only when a stock is cheap -- without letting emotion get in the way of a good investment decision.
Most investors have a list of great stocks they would like to own at the right price. Their watch list might include value stocks that have moved higher after years of trading at low prices or growth stocks they'd like to buy on a pullback. But oftentimes these investors lack a plan to get the stocks they want to own off their watch lists and into their portfolios.
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon's portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.
Pharmaceuticals Division
The Company�� Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented prescription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company�� Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.
The Company�� Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company�� Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson's disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.
Alcon Division
The Company�� Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon's Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon Division's Ophthalmic Pharmaceuticals business combines Alcon's range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division's Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav solution for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.
Sandoz Division
The Company�� Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women's health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals' Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company�� Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world's blood supply. Novartis Vaccines' products include influenza, meningococcal, pediatric, adult and travel vaccines.
The Company�� influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines include Polioral and Quinvaxem.
Consumer Health
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for companion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.
Advisors' Opinion: - [By Rich Smith]
Ahh ... ahh ... achoo!
For one thing, it bought a whole lot of flu drugs to treat flu bugs. On Monday, the DoD awarded twin contracts for flu vaccines to a pair of foreign Big Pharma producers. France's Sanofi (NYSE: SNY ) was awarded a $14 million contract for flu vaccines. Switzerland's Novartis (NYSE: NVS ) got a similar $14 million order.
Best Low Price Companies To Watch In Right Now: Craft Brew Alliance Inc (BREW)
Craft Brew Alliance, Inc., incorporated on May 4, 1981, is an independent craft brewer. The Company is engaged in brewing, marketing and selling of craft beers in the United States. The Company operates two segments: Beer related operations and Pubs and Other. Beer related operations include the brewing and sale of craft beers from its five breweries. Pubs and Other operations primarily include its five pubs, four, of which are located adjacent to its breweries. The Company brews its Widmer Brothers, Redhook and Kona beers in each of its three mainland production breweries, including New Hampshire Brewery, Oregon Brewery and Washington Brewery. The Company also owns and operates a small manual style brewery, primarily used for small batch production at the Rose Quarter in Portland, Oregon. The Company�� beer portfolio is consisted of the Widmer Brothers, Redhook and Kona brand families. On May 2, 2011, the Company sold 42% interest in Fulton Street Brewery, LLC.
The Company�� Widmer Brothers Hefeweizen is a golden, cloudy wheat beer with a pronounced citrus aroma and flavor. This beer is usually served with a lemon slice. Its Drifter Pale Ale is brewed with generous amounts of summit hops. It also includes Drop Top Amber Ale and Rotator India Pale Ale. Initial beers in the series 924 series include the Nelson Imperial IPA and the Pitch Black IPA, which is a Pacific Northwest twist on a traditional IPA, brewed in the style of a Cascadian Dark. Beers in this brand are offered as a draft product and as a four pack for bottles. Widmer Brothers beers include Brothers��Reserve and Alchemy Project. Widmer Brothers seasonal beers are Citra Blonde, Okto, Brrr and W series.
The Redhook family of beers is consisted of sessionable (lower alcohol by volume) and approachable beers. Its Long Hammer IPA is the beer within the brand family and is English pub-style bitter ale with a bold hop aroma and profile that is not overpoweringly bitter. Its
Redhook Pilsner is a crisp, easy-! drinking, golden lager that is modeled after beers originally brewed in Plzen, Czechoslovakia. Redhook ESB is rich, full-bodied amber ale with a smooth flavor profile featuring toasted malts and a pleasant finishing sweetness. Its Copperhook Ale is copper-colored ale with caramel notes and a clean refreshing finish. The Company�� Blueline Series brand is offering from the Redhook brand family for the West Coast beer drinker. These beers are hand crafted by the brewers and are available at its Washington Brewery pub, as well as at select restaurants, bottle shops and public houses in the Seattle, Washington area. Its Brewery Backyard Series is produced at its New Hampshire brewery as a draft product available at the brewery�� pub and at select local establishments. Redhook seasonal beers include Nut Brown Ale, Winterhook Winter Ale and Wit.
The Company�� Kona Beers brand family is consisted of beers that deliver the essence of the Hawaiian Islands that is Always Aloha. The Company�� Longboard Island Lager is a traditionally brewed lager with a delicate, slightly spicy hop aroma that is complimented by a fresh, malt-forward flavor and a smooth, refreshing finish. Its Fire Rock Pale Ale is a crisp, Hawaiian Style pale ale with pronounced citrus and floral hop aromas and flavors that are backed up by a generous malt profile.
Kona seasonal beers include Koko Brown Ale, American brown ale with a deep amber color and rich mahogany hues. This ale has a smoky, roasted nut aroma and flavor, with a coconut twist. Koko Brown Ale is Kona�� spring seasonal. Its Pipeline Porter is smooth and dark, with a roasty aroma and earthy flavor. This ale is brewed with fresh 100% Kona coffee. Its Wailua Wheat is golden, sun-colored ale with a bright, citrusy flavor. This beer is brewed with a touch of tropical passion fruit to impart a slightly tart and crisp finish. Kona offers two variety packs: Island Hopper variety 12-packs and Big Kahuna variety 24-packs. Both packages include the brewe! ry�� Lo! ngboard Island Lager along with Fire Rock Pale Ale and then two of its Aloha series seasonal offerings: Koko Brown, Wailua Wheat and Pipeline Porter.
The Company competes with Heineken, Corona Extra and Guinness.
Advisors' Opinion: - [By Chris Katje]
Publicly traded Craft Brew Alliance (BREW) is the owner of three key craft beer brands. The company, through two mergers, owns the brands Redhook, Widmer, and Kona. One of those brands (Redhook) has a partnership coming with Buffalo Wild Wings that could create coverage of the company's stock and blow revenue estimates out of the water.
- [By Louis Navellier]
The fantastic performance and growth of this company was noted by Portfolio Grader back in August and the stock was upgraded to an A. Shares of SAM stock remain a “strong buy” at the current price. When it comes to beer stocks to buy now, this is one of the most tempting.
Best Booze Stocks to Buy Now -�Craft Brew Alliance (BREW) Craft Brew Alliance (BREW) makes craft beers under three very popular brands for beer aficionados. The Widmar Brothers, Redhook and Kona brands of beer have all received rave reviews … and that’s just one reason BREW is one of the best beer stocks to buy now.
Best Low Price Companies To Watch In Right Now: Halcon Resources Corp (HK)
Halcon Resources Corporation (Halcon Resources), incorporated on February 5, 2004, is an independent energy company focused on the acquisition, production, exploration and development of onshore liquids-rich oil and natural gas assets in the United States. The Company has oil and natural gas reserves located primarily in Texas, North Dakota, Louisiana, Oklahoma and Montana. On August 1, 2012, the Company acquired GeoResources by merger. On December 6, 2012, the Company completed the acquisition of entities owning approximately 81,000 net acres prospective for the Bakken / Three Forks formations primarily located in Williams, Mountrail, McKenzie and Dunn Counties, North Dakota (the Williston Basin Assets), from Petro-Hunt, L.L.C. and Pillar Energy, LLC (the Petro-Hunt parties). As of December 31, 2012, the Company has working interests in approximately 128,000 net acres prospective for the Bakken / Three Forks formations in North Dakota and Montana.
The Company�� Woodbine / Eagle Ford acreage is prospective for the Woodbine, Eagle Ford and other formations, with targeted depths ranging anywhere from 7,000 feet to 10,400 feet. As of December 31, 2012, The Company has approximately 198,000 net acres leased or under contract primarily in Leon, Madison, Grimes, Brazos, and Polk Counties, Texas. The Company is the operator and has a 100% working interest in more than 12,000 net acres in Wichita and Wilbarger Counties, Texas that it is actively water flooding in shallow Cisco aged Pennsylvania sandstone and limestone reservoirs. As of December 31, 2012, the Company produced 484 million barrels of oil equivalent from approximately 700 active producing wells and approximately 230 active water injection wells.
The Company�� position in the La Copita Field covers 3,720 gross acres and 2,829 net acres in Starr County, Texas. As of December 31, 2012, the Company�� average net daily production was 623 barrels of oil equivalent per day. The Company operates 100% of this production a! nd its working interest ranges from 75% to 100%. The Company has various other oil and natural gas properties with varying working interests located across the United States, including the Austin Chalk Trend and Eagle Ford Shale in Texas, the Fitts-Allen Fields in Central Oklahoma, and various other areas across South Louisiana, Montana, North Dakota, New Mexico, and West Virginia.
Advisors' Opinion: - [By Selena Maranjian]
Finally, Graham Capital's biggest closed positions included Hess�and calls on the SPDR S&P 500 ETF. Other closed positions of interest include Halcon Resources (NYSE: HK ) and Pengrowth Energy (NYSE: PGH ) . Oil and gas company Halcon, operating in the promising Bakken region, as well as Texas' productive Eagle Ford shale region, among others, posted 2012 net daily production 128% higher than year-earlier levels, and proven reserves up 417%. The stock was punished after a disappointing earnings result last month, despite surging revenue. Free cash flow has moved into the red, though.
- [By Joel South and Taylor Muckerman]
In the video below, Motley Fool analysts Joel South and Taylor Muckerman discuss a recent operational update from Halcon Resources (NYSE: HK ) , showing even stronger growth than the company had projected. Joel highlights a few recent wells for the company in the Fort Berthold region in North Dakota that have been very strong performers, and discusses the company's large production increases both in that region and in the Eagle Ford region in Texas. He also tells us about the operational efficiencies that have led the company to bring home these higher yields.
- [By Matt DiLallo]
The other risk that can't be overlooked is the threat from ceramic proppants, like those made by�CARBO Ceramics� (NYSE: CRR ) , which could take a greater market share than is currently projected. Referring to the demand chart, frac sand is projected to remain 75% of the proppant market as that market grows. However, some shale plays like the Bakken are forcing producers to turn to higher-cost ceramic proppants because the returns are better.�Halcon Resources� (NYSE: HK ) , for example, pointed out that its strategy to use ceramic proppants was one of the�driving forces�behind its improved returns in the Bakken. The company saw much higher initial production rates, while expecting better estimated ultimate recovery rates from its investment in ceramic proppants. If ceramics do end up taking market share, it could crush my investment in Hi-Crush.
Best Low Price Companies To Watch In Right Now: Assured Guaranty Ltd(AGO)
Assured Guaranty Ltd., through its subsidiaries, provides credit protection products to public finance, infrastructure, and structured finance markets in the United States and internationally. The company offers insurance, reinsurance, and credit derivative products that protect holders of debt instruments and other monetary obligations from defaults in scheduled payments, including scheduled interest and principal payments. It provides policies issued directly to the holders of insured obligations at time of issuance and those issued in the secondary market; and assumed reinsurance contracts written to third parties. The company insures various types of securities, including taxable and tax-exempt obligations issued by the United States or municipal governmental authorities, utility districts, or facilities; notes or bonds issued to finance international infrastructure projects; and asset-backed securities issued by special purpose entities. Assured Guaranty Ltd. markets its credit protection products directly to issuers and underwriters of public finance, infrastructure, and structured finance securities, as well as to investors in such debt obligations. The company was founded in 2003 and is based in Hamilton, Bermuda.
Advisors' Opinion: - [By Selena Maranjian]
Diamond Hill reduced its stake in lots of companies, including Assured Guaranty (NYSE: AGO ) . The company offers a 2% dividend yield, which reflects a recent 11% increase, but it's been struggling lately. Its CEO recently said at a conference that the company is working on new business production but is feeling "pressured in the States." On the plus side, "We actually expect 2013 to be a reasonably good year in the international markets." Assured also won a legal case earlier this year and along with it many millions.
- [By Lauren Pollock]
Assured Guaranty Ltd.'s(AGO) third-quarter profit more than doubled as the bond insurer recorded a gain tied to credit derivatives that masked a decline in net premiums earned. Shares rose 4.7% to $22.75 premarket.
Best Low Price Companies To Watch In Right Now: International Game Technology (IGT)
International Game Technology (IGT) designs, manufactures, and markets electronic gaming equipment and systems worldwide. The company offers casino-style slot machines that determine the game play outcome at the machine; wide area progressive jackpot systems with linked machines across various casinos; central determination system machines connected to a central server that determines the game outcome, encompassing video lottery terminals used primarily in government-sponsored applications and electronic or video bingo machines; and amusement with prize games. Its systems products include applications for casino management, customer relationship marketing (CRM), and server-based games and player management. IGT?s casino management solutions comprise integrated modules for machine accounting, patron management, cage and table accounting, ticket-in/ticket-out, bonusing (jackpots and promotions), and table game automation. The company?s CRM solutions feature integrated market ing and business intelligence modules that provide analytical, predictive, and management tools for maximizing casino operational effectiveness; and server-based solutions enable game delivery to slot machines, computers, mobile phones, tablets, and other networked devices. Its gaming markets comprise the United States, Canada, Europe, the Middle East, Africa, Mexico and South/Central America, Asia, Australia, New Zealand, the Pacific, and the United Kingdom. The company was founded in 1980 and is headquartered in Reno, Nevada.
Advisors' Opinion: - [By Rick Munarriz]
We can start with International Game Technology (NYSE: IGT ) .�The leading provider of gaming machines and systems for the casino industry is giving its investors more slot machine money.
- [By John Divine]
Lastly, slot machine maker International Game Technology (NYSE: IGT ) slumped 7.3%, due largely to negative analyst sentiment. Unlike AMD and Microsoft, IGT doesn't report quarterly results until next Tuesday, so the comments today were sure to attract the attention of some uneasy investors before official numbers come out. A Janney Capital Markets analyst said that the stock's been driven up to a point where it no longer offers newcomers an attractive entry point. On top of that, IGT is set to start losing market share, will see higher costs, and will be able to buy back less stock in the future, according to the report.�
- [By Ben Levisohn]
All good things must come to an end. And so it is with the S&P 500′s six-day winning streak, as AT&T (T), Intuitive Surgical (ISRG), International Game Technology (IGT), Amgen (AMGN) and Netflix (NFLX) helped lead the market lower.
Best Low Price Companies To Watch In Right Now: Fair Isaac Corp (FICO)
Fair Isaac Corporation (FICO), incorporated on May 15, 1987, provides products and services that enable businesses to automate, improve and connect decisions to enhance business performance. The Company operates in three segments: Applications, which include pre-configured Decision Management applications designed for a specific type of business problem or process; Scores, which includes the Company's business-to-business scoring solutions and services, its myFICO solutions for consumers, and associated professional services, and Tools segment, which include software tools that clients can use to create their own custom Decision Management applications, as well as associated professional services. In May 2012, the Company acquired Entiera Inc. In September 2012, it acquired Adeptra Ltd. On April 1, 2013, FICO acquired Infoglide Software Corp.
Applications
The Company develops industry-tailored Decision Management applications, categorized as Applications, which apply analytics, data management and Decision Management software to specific business challenges and processes. These include credit offer prescreening, insurance claims management and others. The Company's Applications primarily serve clients in the banking, insurance, healthcare, and retail sectors. The chief offerings for marketing are the Company's FICO Analytic Offer Manager and FICO Customer Dialogue Manager. These solutions offer a suite of products, capabilities and services designed to integrate the technology and analytic services needed to perform context-sensitive customer acquisition, cross-selling and retention programs and deliver mathematically optimized offers.
The Company provides solutions that enable banks, credit unions, finance companies, installment lenders and other companies to automates and improve the processing of requests for credit or service. The Company provides customer management solutions for banking, where it�� account and customer management product is the FICO TRIAD! Customer Manager. The Company markets and sells TRIAD end-user software licenses, maintenance, consulting services, and strategy designs and evaluation. The Company's fraud management products improve the Company's clients' profitability by predicting the likelihood that a given transaction or customer account is experiencing fraud.
The Company's solutions are designed to detect and prevent a range of fraud and risk types across multiple industries, including credit and debit payment card fraud; e-payment fraud; deposit account fraud; technical fraud and bad debt; healthcare fraud; Medicaid and Medicare fraud, and property and casualty insurance claims fraud, including workers' compensation fraud. FICO fraud solutions protect financial institutions, insurance companies and government agencies from losses and damaged customer relationships caused by fraud and related criminal behavior.
FICO Fraud Predictor with Merchant Profiles is used in conjunction with Falcon Fraud Manager on payment card monitoring for credit and debit to improve fraud detection rates through the inclusion of merchant profiles. In addition to the Falcon products, the Company offers FICO Card Alert Service. Card Alert Service is a solution for fighting ATM debit fraud. The Card Alert Service identifies counterfeit payment cards and reports them to issuers. The Company offers FICO Economic Impact Service, which uses time series modeling of the macro economy to allow lenders to forecast future credit risk performance based on their views of the economy. Adeptra's software as a service (SaaS) platform enables financial services institutions and other businesses to take advantage of the explosion in mobile communication in order to manage risk, fight fraud and improve the customer experience, all in real time.
The Company competes with Acxiom, Epsilon, Equifax, Experian, Harte-Hanks, InfoUSA, KnowledgeBase, Merkle, TargetBase, CGI, NICE Systems, BAE, SAS, ACI Worldwide, Emdeon, Ingenix, ViPS, MedSt! at, Veris! k Analytics and IBM.
Scores
The Company develops credit scores based on third-party data. The Company's FICO Scores are used in most United States credit decisions, by the banks and credit card organizations, as well as by mortgage and auto loan originators. These scores provide a consistent and objective measure of an individual's credit risk. Credit grantors use the FICO Scores to prescreen candidates for solicitation, to evaluate applicants for new credit and to review existing accounts. The FICO Scores are calculated based on scoring models and implemented on third-party data. The version of the FICO Score for United States and Canadian lenders is the FICO 8 Score. The Company's other solutions include The FICO Credit Capacity Index and The FICO Economic Impact Index.
The Company competes with Experian and Experian-Scorex (U.S. partner), TransUnion and TransUnion International, Equifax, VantageScore, CRIF, LexisNexis and ChoicePoint.
Tools
The Company provides software products that businesses use to build their own tailored Decision Management applications. In contrast to its packaged Applications developed for specific industry applications, the Company�� Tools support the addition of Decision Management capabilities to virtually any application or operational system. These tools are sold as licensed software, and can be used by themselves or together to advance a client�� Decision Management initiatives. The Company uses these tools as common software components for its own Decision Management applications. The principal products offered are software tools include Rules Management, Predictive Modeling and Optimization.
The Company competes with IBM, SAS, Pegasystems and Angoss.
Advisors' Opinion: - [By Rich Smith]
Alamy You've probably heard by now that in some vague way, your credit rating has something to do with the premiums your auto insurance company charges you for coverage. But if you're like me, you've probably never quite understood the details of how this work. Fortunately, the good folks at InsuranceQuotes.com -- a subsidiary of Bankrate (RATE) -- recently published a report that draws back the curtain on this little-understood quirk of the insurance industry. Blame it on FICO Used to be, the rate you paid for insuring your car was tied primarily to demographic and personal factors that were clearly connected to the risk that you'd damage your car and ask the insurance company to pay for it: things like your age, sex, marital status, and driving history. It won't surprise anyone that younger, unmarried men are more likely to be risky drivers than soccer moms, and should therefore pay higher premiums. But about 20 years ago, the folks at Fair Isaac Corporation (FICO) found a correlation between low credit scores and a higher risk of filing an insurance claim. That's not causation, of course -- having bad credit doesn't somehow cause you to crash your car. But according to FICO, "people who choose to effectively manage their finances are also less likely to have future insurance losses." Conversely, there is a "statistical correlation between a person's credit score and the likelihood that he or she will file an auto insurance claim in the future." Suddenly, FICO had a new way to hawk its credit histories to insurance companies -- and insurance companies had a new excuse to raise your rates. News Flash: Everybody Does It Ever since, insurance companies have used this finding to tweak the rates they charge you for insurance. Today, says InsuranceQuotes, "about 97 percent of U.S. insurance companies" do it. But how do they do it, exactly?
- [By WWW.DAILYFINANCE.COM]
Incoming college freshmen receive dozens of warnings:
Mom and dad caution them to not get carried away with extracurricular activities and instead focus on their grades. Older siblings kindly suggest avoiding any beverage with the word "jungle" in the name. Financial experts yell, scream and throw their arms in the air about avoiding credit cards. While jungle juice should be avoided, there is a case for most college students to sign up for a credit card. Students who describe themselves as impulsive, spenders or forgetful may need to wait. Here are three reasons why a credit card will set them up for a healthy financial future. 1. Credit Cards Help Establish Credit History A credit card is a simple tool to both establish credit history and begin working toward a good credit score. Student loans help establish credit and can positively impact a credit score. However, part of Fair Isaac's (FICO) FICO scoring model depends on diversity of credit. And responsible use of a credit card -– making on-time payments, for example -– is a simple way to increase a credit score. Credit cards also let students without loans establish their credit and spend four years proving they are responsible borrowers before graduation. Lest we forget, recent grads who don't want to return to their parents' basement will need a credit score to get their own apartment or house. Parents concerned their child can't handle the credit limit associated with a credit card should consider having their child apply for a secured card to prove their responsibility before upgrading to the real McCoy. 2. Students Don't Always Have Cash Some financial experts advise using cash to avoid debt because mindlessly swiping plastic doesn't register as spending money. Except cash is quickly becoming a relic of the past. Plenty of young men and women are used to debit cards and use apps like PayPal or Venmo to pay back a friend instead of cutting a check or getting cash out at the ATM. - [By Dan Caplinger]
A recent study from Fair Isaac's (NYSE: FICO ) FICO took a look at the demographics of credit card use lately. What they found is that outstanding credit card debt among 18- to 29-year-olds dropped from just over $3,000 in late 2007 to a bit over $2,000 last October. That move comes as part of a broader reduction in overall indebtedness, with drops in outstanding mortgage, auto, and most other debt more than offsetting a substantial rise in student-loan debt. Even more surprisingly, the proportion of young adults going without credit cards entirely has risen to nearly one in six, almost double the level from late 2005.
- [By Dan Caplinger]
What we do know
Credit-reporting agencies aren't entirely opaque about what goes into their credit score calculations. For instance, Fair Isaac (NYSE: FICO ) , the company behind the popular FICO score, offers a detailed explanation of what goes into every person's score. A strong payment history without delinquencies or late payments carries the most weight, making up 35% of the FICO score, while 30% comes from how the amounts you owe compare to the total credit you have available to you. Smaller percentages of the score come from other areas, including the length of your credit history, the amount of new credit you've taken out recently, and how wide a mix of different types of credit you have outstanding.
Best Low Price Companies To Watch In Right Now: William Hill PLC (WMH)
William Hill PLC is a United Kingdom-based gambling company. The Company�� business is to provide its customers with a range of sports betting and gaming opportunities. It is a bookmaker providing fixed odds sports betting. It also offers gaming opportunities. The Company�� segments include Retail distribution channel, which includes activity undertaken in LBOs, including gaming machines; Online segment, which includes activity undertaken online, including an online sportsbook, online casino, online poker sites and other gaming products; Telephone segment, which includes its telephone betting services; US segment, comprises all activity undertaken in the United States; Other activities include on-course betting and greyhound stadia operations. In April 2013, it acquired the remaining 29% stake in William Hill Online from its joint venture partner Playtech Ltd. Effective September 2, 2013, William Hill PLC acquired Miapuesta.es, a provider of gaming and sports betting services.
Advisors' Opinion: - [By Inyoung Hwang]
Prudential Plc (PRU), which generated 32 percent of its operating income from Asia last year, climbed to its highest price since at least 1988. William Hill (WMH) Plc lost 3.2 percent after JPMorgan Chase & Co. lowered its rating on the bookmaker. Anglo American Plc (AAL) declined 1.4 percent after saying that production at its Kumba (KIO) Iron Ore Ltd. unit fell.
- [By Inyoung Hwang]
Royal Bank of Scotland Group Plc sank 3.3 percent after reporting results and naming the head of its U.K. consumer unit as chief executive officer. William Hill Plc (WMH) dropped the most in four years after the bookmaker posted earnings that missed analysts��projections. International Consolidated Airlines Group SA (IAG) rose to a five-year high as the parent of British Airways reported an operating profit in the second quarter.
